CD274 and metastatic neoplasm: In patients with metastatic disease, the CheckMate-227 study (evaluating first-line Ipi+Nivo)37 and the CheckMate-9LA study (evaluating Ipi+Nivo+CT)38 suggested notable activity of Ipi in PD-L1-negative tumors.